Koligo Therapeutics (ASX:KOL) Operating Margin %: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Koligo Therapeutics Operating Margin %?

Koligo Therapeutics ASX:KOL Operating Margin % is 0.00% as of . 20.

Operating Margin % is calculated as Operating Income divided by its Revenue. Koligo Therapeutics's Operating Income for the six months ended in . 20 was A$0.00 Mil. Koligo Therapeutics's Revenue for the six months ended in . 20 was A$0.00 Mil. Therefore, Koligo Therapeutics's Operating Margin % for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for Koligo Therapeutics's Operating Margin % or its related term are showing as below:


ASX:KOL's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.33
* Ranked among companies with meaningful Operating Margin % only.

Koligo Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Koligo Therapeutics's Operating Income for the six months ended in . 20 was A$0.00 Mil.

Koligo Therapeutics  (ASX:KOL) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.

Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Koligo Therapeutics Operating Margin % Related Terms

Koligo Therapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Koligo Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Koligo Therapeutics Operating Margin % Chart

Koligo Therapeutics Annual Data
Trend
Operating Margin %

Koligo Therapeutics Semi-Annual Data
Operating Margin %

ASX:KOL vs : Operating Margin % Comparison

For the Biotechnology subindustry, Koligo Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Koligo Therapeutics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Koligo Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Koligo Therapeutics's Operating Margin % falls into.


Koligo Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Koligo Therapeutics's Operating Margin % for the fiscal year that ended in . 20 is calculated as

Operating Margin %=Operating Income (A: . 20 ) / Revenue (A: . 20 )
= /
= %

Koligo Therapeutics's Operating Margin % for the quarter that ended in . 20 is calculated as

Operating Margin %=Operating Income (Q: . 20 ) / Revenue (Q: . 20 )
= /
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Koligo Therapeutics (ASX:KOL) has a Operating Margin % of 0.00% as of . 20. Operating margin is the ratio of total operating income to net sales. View historical data on Koligo Therapeutics and its competitors.
Is Koligo Therapeutics' Operating Margin % too high?
Koligo Therapeutics' current Operating Margin % is 0.00%.
How does Koligo Therapeutics' Operating Margin % compare to ?
Koligo Therapeutics' Operating Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Koligo Therapeutics and its competitors. Koligo Therapeutics's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Koligo Therapeutics stock overvalued right now?
Koligo Therapeutics (ASX:KOL) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Koligo Therapeutics (ASX:KOL), the current Operating Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Koligo Therapeutics Business Description

Comparable Companies